DISORDERS OF PROLACTIN SECRETION
Top Cited Papers
- 25 May 2005
- journal article
- review article
- Published by Elsevier
- Vol. 30 (3) , 585-610
- https://doi.org/10.1016/s0889-8529(05)70203-6
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma ShrinkageJournal of Clinical Endocrinology & Metabolism, 1997
- Abnormal Transduction Mechanisms in Pituitary AdenomasHormone Research, 1997
- Pregnancy outcome after treatment with the ergot derivative, cabergolineReproductive Toxicology, 1996
- Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergolineJournal of Clinical Endocrinology & Metabolism, 1996
- Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteersJournal of Clinical Endocrinology & Metabolism, 1995
- Bromocriptine in pregnancy: Safety aspectsJournal of Molecular Medicine, 1987
- Low Doses of Dopamine Agonists in the Long-Term Treatment of MacroprolactinomasNew England Journal of Medicine, 1985
- Follow-Up of Children Born of Bromocriptine-Treated MothersHormone Research, 1985
- Pergolide for the Treatment of Pituitary Tumors Secreting Prolactin or Growth HormoneNew England Journal of Medicine, 1983
- Vasoactive intestinal polypeptide: Release into hypophyseal portal bloodLife Sciences, 1979